NUVB News
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European CountriesPR NewswireNEW YORK, Oct. 29, 2026 New sites in the UK, France...
PR Newswire
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European Countries Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European CountriesPR NewswireNEW YORK, Oct. 29, 2026 New sites in the UK, France...
PR Newswire
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026 Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026PR NewswireNEW YORK, Oct. 21, 2026 NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation...
PR Newswire
Why Is Nuvation Bio Stock Gaining Thursday?
Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 years of clinical benefit in ROS1+ NSCLC.read more...
Benzinga
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in TKI-Nave Advanced ROS1-Positive Non-Small Cell Lung Cancer
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib) with Updated Duration of Response in TKI-Nave Advanced ROS1-Positive Non-Small Cell Lung Cancer Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI (taletrectinib...
PR Newswire
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI...
PR Newswire
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is...
Cramer calls Nuvation Bio a pure spec, prefers CoreWeave over IREN, is unsure on Seneca, cautious on NuScale, and approves Box.read more...
Benzinga
Cramer's lightning round: Nuvation Bio 'is a pure spec'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...
CNBC: Mad Money with Jim Cramer
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Nuvation Bio (NUVB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Nuvation Bio to Participate in Upcoming Investor Conferences
Nuvation Bio to Participate in Upcoming Investor Conferences Nuvation Bio to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, Sept. 2, 2026 NEW YORK, Sept. 2, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest...
PR Newswire
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why
Nuvation Bio (NUVB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks